BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
BioAge Labs, Inc.NASDAQ: BIOA
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$237.74M, compared with -$247.17M a year earlier.
Context
- Net debt amounted to 59.8% of total assets at the end of Q1 FY2026, down 12.1 pp from a year earlier.
- Net debt increased in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +3.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (183.33M) USD
- Year-over-year change
- +47.0%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (183.33M) | +47.0% |
| FY2024 | 2024-12-31 | (345.65M) | -1193.5% |
| FY2023 | 2023-12-31 | 31.61M | +225.5% |
| FY2022 | 2022-12-31 | (25.18M) | — |
Net Debt vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +3.8% is the 6th highest of 9, against a peer median of +21.6%.
- Net debt amounts to 59.8% of total assets for BIOA, versus a peer median of 15.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | $125.14M USD | — | — | 53.9% | |
| Mar 2026 | $50.74M USD | +30.7% | -7.0% | 12.8% | |
| Mar 2026 | $17.36M USD | +136.9% | — | 15.7% | |
| Mar 2026 | $10.35M USD | -60.1% | +399.7% | 10.5% | |
| Mar 2026 | -$51.67M USD | +52.0% | — | 34.6% | |
| Mar 2026 | -$78.68M USD | +33.3% | — | 29.5% | |
| Mar 2026 | -CA$85.97M CAD | -136.6% | — | 7.7% | |
| Mar 2026 | -CA$88.85M CAD | -10.7% | — | 14.7% | |
| Mar 2026 | -$90.19M USD | +12.5% | — | 60.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | -$237.74M USD | +3.8% | — | 59.8% |
| Peer median (excluding BIOA) | — | +21.6% | +196.4% | 15.7% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.